Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Therapies02:49

Cancer Therapies

10.5K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.5K
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

6.5K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
6.5K
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

5.9K
5.9K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.9K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Specialized Care Centers and Settings-II01:30

Specialized Care Centers and Settings-II

1.3K
Rural Health Centers
Rural health centers are specialized care facilities in remote locations with very few medical personnel. The primary care providers who run the centers are mostly Registered Nurse Practitioners. Here, emergency treatment is provided to critically ill or injured patients before they are transferred to the closest hospital. Fortunately, due to advancement in technology, many rural healthcare facilities and professionals have easy access to diagnostic and treatment...
1.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Major wound complications after conventional preoperative radiotherapy in STS patients: incidence, predictors, and timing.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·2026
Same author

Health-Related Quality of Life in Patients With a Head and Neck Sarcoma: A Mixed-Methods Study.

Head & neck·2025
Same author

The role of whole-genome sequencing for guiding systemic therapy in patients with soft tissue sarcoma.

ESMO open·2025
Same author

Pandemic driven preoperative moderate hypofractionated radiotherapy for soft tissue sarcomas.

European journal of cancer (Oxford, England : 1990)·2025
Same author

Interleukin-6 in relation to early recurrence in primary, localized soft tissue sarcoma: An addition for existing risk classification systems?

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·2024
Same author

Magnetic seed localization is feasible for non-palpable melanoma, Merkel cell carcinoma, and soft tissue sarcoma lesions.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·2024
Same journal

[Insulin intoxications caused by falsified semaglutide].

Nederlands tijdschrift voor geneeskunde·2026
Same journal

[Professional skepticism in medical research].

Nederlands tijdschrift voor geneeskunde·2026
Same journal

[Improving mobility in painful osteoarthritis].

Nederlands tijdschrift voor geneeskunde·2026
Same journal

[The effectiveness and costs of the Back At work After Surgery (BAAS) work-integrated care pathway on return to work for patients receiving knee arthroplasty].

Nederlands tijdschrift voor geneeskunde·2026
Same journal

[The rise of genetic therapies: urgent moral and societal questions].

Nederlands tijdschrift voor geneeskunde·2026
Same journal

[A man with a wound on his elbow].

Nederlands tijdschrift voor geneeskunde·2026
See all related articles

Related Experiment Video

Updated: Mar 12, 2026

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma
09:25

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma

Published on: October 14, 2016

19.7K

[Network of specialized sarcoma centres].

W J van Houdt1, J M Kerst, R L Haas

  • 1Antoni van Leeuwenhoek, Amsterdam.

Nederlands Tijdschrift Voor Geneeskunde
|November 3, 2016
PubMed
Summary
This summary is machine-generated.

Rare cancer treatment, like soft tissue sarcoma, improves with specialized and international networks. Centralized expertise ensures better diagnostic work-up and oncological outcomes for patients with rare tumors.

More Related Videos

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
07:55

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

15.3K
The In ovo CAM-assay as a Xenograft Model for Sarcoma
12:44

The In ovo CAM-assay as a Xenograft Model for Sarcoma

Published on: July 17, 2013

26.5K

Related Experiment Videos

Last Updated: Mar 12, 2026

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma
09:25

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma

Published on: October 14, 2016

19.7K
Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
07:55

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

15.3K
The In ovo CAM-assay as a Xenograft Model for Sarcoma
12:44

The In ovo CAM-assay as a Xenograft Model for Sarcoma

Published on: July 17, 2013

26.5K

Area of Science:

  • Oncology
  • Rare Cancers
  • Cancer Treatment Networks

Background:

  • Non-specialized centers manage few rare cancer cases, leading to suboptimal diagnosis and treatment.
  • This disparity results in poorer oncological outcomes for patients with rare malignancies.
  • Soft tissue sarcoma serves as a key example of a rare tumor requiring specialized care.

Purpose of the Study:

  • To highlight the necessity of specialized cancer centers for rare tumor management.
  • To emphasize the value of national and international expert networks in optimizing rare cancer therapy.
  • To illustrate the benefits of collaborative networks using soft tissue sarcoma treatment.

Main Methods:

  • Review of treatment protocols for rare cancers, focusing on soft tissue sarcoma.
  • Analysis of outcomes in patients treated at non-specialized versus specialized centers.
  • Assessment of the role of multidisciplinary teams and international collaborations.

Main Results:

  • Inadequate diagnostic work-up and treatment are common in non-specialized settings for rare cancers.
  • Specialized centers and networks demonstrate improved oncological outcomes.
  • Collaborative international expertise enhances tailor-made therapy for rare tumors.

Conclusions:

  • Multidisciplinary expertise within specialized cancer centers is crucial for rare cancer patients.
  • International networks are essential for providing advanced, individualized treatment for rare tumors.
  • Improved patient outcomes in rare cancers are achievable through centralized and networked care models.